Silica nanoparticles for brain cancer

Introduction

Brain cancer is a debilitating disease with a poor survival rate. There are significant challenges for effective treatment due to the presence of the blood-brain barrier (BBB) and blood-tumor barrier (BTB) which impedes drug delivery to tumor sites. Many nanomedicines have been tested in improving both the survival and quality of life of patients with brain cancer with the recent focus on inorganic nanoparticles such as silica nanoparticles (SNPs). This review examines the use of SNPs as a novel approach for diagnosing, treating, and theranostics of brain cancer.

Areas covered

The review provides an overview of different brain cancers and current therapies available. A special focus on the key functional properties of SNPs is discussed which makes them an attractive material in the field of onco-nanomedicine. Strategies to overcome the BBB using SNPs are analyzed. Furthermore, recent advancements in active targeting, combination therapies, and innovative nanotherapeutics utilizing SNPs are discussed. Safety considerations, toxicity profiles, and regulatory aspects are addressed to provide an understanding of SNPs’ translational potential.

Expert opinion

SNPs have tremendous prospects in brain cancer research. The multifunctionality of SNPs has the potential to overcome both the BBB and BTB limitations and can be used for brain cancer imaging, drug delivery, and theranostics. The insights provided will facilitate the development of next-generation, innovative strategies, guiding future research toward improved diagnosis, targeted therapy, and better outcomes in brain cancer patients.

Read more here

Yuran Feng,Yuxue Cao,Ravi Singh,Taskeen Iqbal Janjua & Amirali Popat, Silica nanoparticles for brain cancer

Received 24 Aug 2023, Accepted 18 Oct 2023, Accepted author version posted online: 31 Oct 2023, https://doi.org/10.1080/17425247.2023.2273830

Read also the article:

• Lipid nanostructures for targeting brain cancer 
• Review of the efficacy of nanoparticle-based drug delivery systems for cancer treatment